NCT04321954View on ClinicalTrials.gov

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

November 13, 2026

Conditions
Differentiated Thyroid CancerAdvanced Cancer
Interventions
DRUG

LENVATINIB

Orally

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

77030

MD Anderson Cancer Center, Houston

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Massachusetts Eye and Ear Infirmary

OTHER